Report Overview

China Mucopolysaccharidosis-I Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Mucopolysaccharidosis typeI (MPSI) is a rare disease in which the body is missing or does not have enough of an enzyme needed to break down long chains of sugar molecules. These chains of molecules are called glycosaminoglycans. The global prevalence of MPS I is estimated to be 1/100,000, with Hurler syndrome accounting for 57% of cases, Hurler- Scheie syndrome accounting for 23% of cases and Scheie syndrome accounting for 20% of cases.



Market Drivers

China is a growing market for mucopolysaccharidosis-1 due to factors such as increase in global prevalence rate (1/100,000). Other factors that are contributes to the growth of market are awareness campaign by various organizations, affordable reimbursement scenario for treatment, the growing necessity for advanced therapeuticsand improved R&D activities.

However, there are some restraining factors for growth of mucopolysaccharidosis-1 therapeutics market in China such as high cost of medicines, misdiagnosis of the disease and limitations of medical insurance coverage.